BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19934299)

  • 1. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
    Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
    Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.
    Mader EK; Butler G; Dowdy SC; Mariani A; Knutson KL; Federspiel MJ; Russell SJ; Galanis E; Dietz AB; Peng KW
    J Transl Med; 2013 Jan; 11():20. PubMed ID: 23347343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
    Liu C; Russell SJ; Peng KW
    Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
    Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
    Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.
    Ong HT; Federspiel MJ; Guo CM; Ooi LL; Russell SJ; Peng KW; Hui KM
    J Hepatol; 2013 Nov; 59(5):999-1006. PubMed ID: 23867315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.
    Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ
    Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
    Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
    PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
    Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
    Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity.
    Castleton A; Dey A; Beaton B; Patel B; Aucher A; Davis DM; Fielding AK
    Blood; 2014 Feb; 123(9):1327-35. PubMed ID: 24345754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus.
    Suksanpaisan L; Russell SJ; Peng KW
    Cancer Gene Ther; 2014 Jun; 21(6):256-60. PubMed ID: 24874841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
    BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.
    Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J
    J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.
    Liu YP; Tong C; Dispenzieri A; Federspiel MJ; Russell SJ; Peng KW
    Cancer Gene Ther; 2012 Mar; 19(3):202-11. PubMed ID: 22116376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
    Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
    Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
    Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
    Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.